Tests a 3D skin scanner for measuring Kaposi sarcoma lesions
Tests a 3D scanner against manual measurement of skin lesions in adults.
Plain-language title generated from the registry record
Registry title: Precision Imaging to Evaluate Kaposi Sarcoma
Key facts
- Where
- Kampala, UgandaSee the site
Where in Uganda
- Infectious Diseases Institute, Makerere UniversityKampala, UgandaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT06898203
- Record updated
- 21 September 2026
- Original description
AIMS 2 \& 3:Read full original descriptionShow less
Precision Imaging to Evaluation Kaposi Sarcoma (PRIME-KS)
AIMS 2 \& 3:
In this study the investigators seek to formally compare reproducibility and accuracy of KS lesion size measurements between SkinScan3D and the current standard of care manual measurement method. The investigators will then test the SS3D device on 100 patients in a variety of real-world practice locations to determine whether the device will be usable, acceptable, appropriate, and feasible in routine care settings.
Inclusion: Adults age ≥18 years old; Histopathology-confirmed Kaposi Sarcoma; At least 3 skin lesions; Capable of informed consent; On treatment for Kaposi Sarcoma; Adults age ≥18 years old; Histopathology-confirmed Kaposi Sarcoma; Capable of informed consent; Initiating treatment for Kaposi Sarcoma.
Exclusion: Prior or ongoing Kaposi Sarcoma treatment; Patients not initiating Kaposi Sarcoma treatment; Very ill patients requiring hospitalization; Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2.